Abstract
Viral vectors are the most effective means to deliver genes into cells. Evolution of viruses over the years has enabled them to adopt several strategies not only to enter but also infect a wide range of cells. Making use of this property, scientists have manipulated viruses to express therapeutic genes. These viruses serve as vehicles for gene delivery and are referred to as viral vectors. The ones that are currently used in gene therapy include retroviral vectors, lentiviral vectors, adenoviral vectors, adeno-associated viral vectors, and foamy viral vectors. Each of them has their own salient features that are both beneficial and harmful. Retroviral vectors belonging to the family Retroviridae were among the first viral vectors used in gene therapy clinical trials. Their genetic material is in the form of RNA. The ability of retroviruses to integrate into the host genome makes them a permanent resident of the cell. The Retroviridae family is further divided into two subfamilies and seven genera, out of which gammaretrovirus, lentivirus, and foamy virus are the most widely used. Gammaretroviral vectors which have been a part of nearly 21% of gene therapy clinical trials were developed from the prototype Moloney murine leukemia virus and hence referred to as MoMLV-based retroviral vectors. The gammaretroviral vector genome ranges in size from 9 to 11 kb and is composed of two long terminal repeats (LTRs) one each at the 3′ and 5′ ends and three essential genes gag, pol, and env which code for proteins required for viral packaging. Reports of insertional mutagenesis and clonal proliferation due to integration of gammaretrovirus into the LMO2 proto-oncogene raised concerns about safety of its application for human gene therapy. Another drawback of this virus is that it can transduce only rapidly proliferating cells. So, in order to successfully target terminally differentiated or largely quiescent cells such as stem cells, lentiviruses are used as they could infect both dividing and nondividing cells fairly efficiently. Unlike gammaretroviruses, lentiviruses do not require cells to be in active mitosis while entering. Over the past three decades, three different generations of lentiviral vectors have been developed, each generation significantly improved over the preceding one. Safety has always been a concern with the use of all viral vectors due to the adverse events reported such as immune response in the case of adenoviral vectors and insertional mutagenesis in the case of retroviral vectors. Recently, third-generation self-inactivating (SIN) lentiviral vectors have been proven to be very efficient and also safer when compared to gammaretroviral vectors which were used in earlier clinical trials. Despite integrating into active transcription units, lentiviral vectors were reported to have a safer integration profile compared to gammaretroviral vectors. Foamy viruses belong to the genera of spumavirus. Analysis of integration sites of foamy viruses in HSCs has shown a unique and safe integration profile compared to both gamma and lentiviruses. Reports from ongoing clinical trials might answer emerging questions related to their safety and efficacy in human gene therapy applications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Warnock JN, Daigre C, Al-Rubeai M (2011) Introduction to viral vectors. Methods Mol Biol 737:1–25
Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7(1):33–40
Bessis N, GarciaCozar FJ, Boissier MC (2004) Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11(Suppl 1):S10–S17
Russell DW, Hirata RK (1998) Human gene targeting by viral vectors. Nat Genet 18(4):325–330
Fields BN, Knipe DM, Howley PM (2007) Fields virology. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia
Liu W, Liu Z, Cao X, Cao Z, Xue L, Zhu F et al (2007) Recombinant human foamy virus, a novel vector for neurological disorders gene therapy, drives production of GAD in cultured astrocytes. Mol Ther 15(10):1834–1841
Weiss RA (1996) Reverse transcription. Foamy viruses bubble on. Nature 380(6571):201
Hill CL, Bieniasz PD, McClure MO (1999) Properties of human foamy virus relevant to its development as a vector for gene therapy. J Gen Virol 80(Pt 8):2003–2009
Maetzig T, Galla M, Baum C, Schambach A (2011) Gammaretroviral vectors: biology, technology and application. Viruses 3(6):677–713
Barquinero J, Eixarch H, Perez-Melgosa M (2004) Retroviral vectors: new applications for an old tool. Gene Ther 11(Suppl 1):S3–S9
Kraunus J, Zychlinski D, Heise T, Galla M, Bohne J, Baum C (2006) Murine leukemia virus regulates alternative splicing through sequences upstream of the 5′ splice site. J Biol Chem 281(49):37381–37390
Zychlinski D, Erkelenz S, Melhorn V, Baum C, Schaal H, Bohne J (2009) Limited complementarity between U1 snRNA and a retroviral 5′ splice site permits its attenuation via RNA secondary structure. Nucleic Acids Res 37(22):7429–7440
Sharma S, Miyanohara A, Friedmann T (2000) Separable mechanisms of attachment and cell uptake during retrovirus infection. J Virol 74(22):10790–10795
Freed EO, Ross SR (2004) Retroviruses 2004: review of the 2004 cold Spring Harbor retroviruses conference. Retrovirology 1:25
Fortin JF, Cantin R, Tremblay MJ (1998) T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1. J Virol 72(3):2105–2112
Plochmann K, Horn A, Gschmack E, Armbruster N, Krieg J, Wiktorowicz T et al (2012) Heparan sulfate is an attachment factor for foamy virus entry. J Virol 86(18):10028–10035
Overbaugh J, Miller AD, Eiden MV (2001) Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins. Microbiol Mol Biol Rev 65(3):371–389
Sommerfelt MA (1999) Retrovirus receptors. J Gen Virol 80(Pt 12):3049–3064
Miller AD (1996) Cell-surface receptors for retroviruses and implications for gene transfer. Proc Natl Acad Sci USA 93(21):11407–11413
Fassati A, Goff SP (2001) Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 75(8):3626–3635
Telesnitsky A, Goff SP (1997) Reverse transcriptase and the generation of retroviral DNA. In: Coffin JM, Hughes SH, Varmus HE (eds) Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor
Trono D (1992) Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol 66(8):4893–4900
Zhu J, Cunningham JM (1993) Minus-strand DNA is present within murine type C ecotropic retroviruses prior to infection. J Virol 67(4):2385–2388
Roe T, Reynolds TC, Yu G, Brown PO (1993) Integration of murine leukemia virus DNA depends on mitosis. EMBO J 12(5):2099–2108
Prizan-Ravid A, Elis E, Laham-Karam N, Selig S, Ehrlich M, Bacharach E (2010) The gag cleavage product, p12, is a functional constituent of the murine leukemia virus pre-integration complex. PLoS Pathog 6(11):e1001183
Studamire B, Goff SP (2010) Interactions of host proteins with the murine leukemia virus integrase. Viruses 2(5):1110–1145
Gruter P, Tabernero C, von Kobbe C, Schmitt C, Saavedra C, Bachi A et al (1998) TAP, the human homolog of Mex67p, mediates CTE-dependent RNA export from the nucleus. Mol Cell 1(5):649–659
Bogerd HP, Echarri A, Ross TM, Cullen BR (1998) Inhibition of human immunodeficiency virus rev and human T-cell leukemia virus rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. J Virol 72(11):8627–8635
Miller AD (1990) Retrovirus packaging cells. Hum Gene Ther 1(1):5–14
Kim SH, Yu SS, Park JS, Robbins PD, An CS, Kim S (1998) Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 72(2):994–1004
Hildinger M, Abel KL, Ostertag W, Baum C (1999) Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol 73(5):4083–4089
Yu SS, Kim JM, Kim S (2000) High efficiency retroviral vectors that contain no viral coding sequences. Gene Ther 7(9):797–804
Sinn PL, Sauter SL, PB MC Jr (2005) Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther 12(14):1089–1098
Zentilin L, Qin G, Tafuro S, Dinauer MC, Baum C, Giacca M (2000) Variegation of retroviral vector gene expression in myeloid cells. Gene Ther 7(2):153–166
Bestor TH (2000) Gene silencing as a threat to the success of gene therapy. J Clin Investig 105(4):409–411
Hantzopoulos PA, Sullenger BA, Ungers G, Gilboa E (1989) Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc Natl Acad Sci USA 86(10):3519–3523
Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM (1998) Development of a self-inactivating lentivirus vector. J Virol 72(10):8150–8157
Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72(12):9873–9880
Lori F, di Marzo Veronese F, de Vico AL, Lusso P, Reitz MS Jr, Gallo RC (1992) Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol 66(8):5067–5074
Lewis PF, Emerman M (1994) Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 68(1):510–516
Schambach A, Baum C (2008) Clinical application of lentiviral vectors – concepts and practice. Curr Gene Ther 8(6):474–482
Chang AH, Sadelain M (2007) The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. Mol Ther 15(3):445–456
Aiken C (1997) Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 71(8):5871–5877
Yamamoto T, Tsunetsugu-Yokota Y (2008) Prospects for the therapeutic application of lentivirus-based gene therapy to HIV-1 infection. Curr Gene Ther 8(1):1–8
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259):263–267
Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110(4):521–529
Nienhuis AW, Dunbar CE, Sorrentino BP (2006) Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13(6):1031–1049
Cereseto A, Giacca M (2004) Integration site selection by retroviruses. AIDS Rev 6(1):13–21
Daniel R, Smith JA (2008) Integration site selection by retroviral vectors: molecular mechanism and clinical consequences. Hum Gene Ther 19(6):557–568
Linial ML (1999) Foamy viruses are unconventional retroviruses. J Virol 73(3):1747–1755
Bodem J, Lochelt M, Yang P, Flugel RM (1997) Regulation of gene expression by human foamy virus and potentials of foamy viral vectors. Stem Cells 15(Suppl 1):141–147
Schweizer M, Falcone V, Gange J, Turek R, Neumann-Haefelin D (1997) Simian foamy virus isolated from an accidentally infected human individual. J Virol 71(6):4821–4824
Meiering CD, Linial ML (2001) Historical perspective of foamy virus epidemiology and infection. Clin Microbiol Rev 14(1):165–176
Herchenroder O, Renne R, Loncar D, Cobb EK, Murthy KK, Schneider J et al (1994) Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz): high homology to human foamy virus (HFV). Virology 201(2):187–199
Müllers E (2013) The foamy virus gag proteins: what makes them different? Viruses 5(4):1023–1041
Löchelt M, Yu SF, Linial ML, Flügel RM (1995) The human foamy virus internal promoter is required for efficientgene expression and infectivity. Virology 206(1):601–610
Yang P, Zemba M, Aboud M, Flügel RM, Löchelt M (1997) Deletion analysis of both the long terminal repeat and the internal promoters of the human foamy virus. Virus Genes 15(1):17–23
Kang Y, Blair WS, Cullen BR (1998) Identification and functional characterization of a high-affinity Bel-1 DNA binding site located in the human foamy virus internal promoter. J Virol 72(1):504–511
Azran I, Schavinsky-Khrapunsky Y, Aboud M (2004) Role of tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology 1:20
Baunach G, Maurer B, Hahn H, Kranz M, Rethwilm A (1993) Functional analysis of human foamy virus accessory reading frames. J Virol 67(9):5411–5418
Lee AH, Lee HY, Sung YC (1994) The gene expression of human foamy virus does not require a post-transcriptional transactivator. Virology 204(1):409–413
Muranyi W, Flugel RM (1991) Analysis of splicing patterns of human spumaretrovirus by polymerase chain reaction reveals complex RNA structures. J Virol 65(2):727–735
Hahn H, Baunach G, Brautigam S, Mergia A, Neumann-Haefelin D, Daniel MD et al (1994) Reactivity of primate sera to foamy virus gag and bet proteins. J Gen Virol 75(Pt 10):2635–2644
Flugel RM (1991) Spumaviruses: a group of complex retroviruses. J Acquir Immune Defic Syndr 4(8):739–750
Yu SF, Linial ML (1993) Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay. J Virol 67(11):6618–6624
Bock M, Heinkelein M, Lindemann D, Rethwilm A (1998) Cells expressing the human foamy virus (HFV) accessory bet protein are resistant to productive HFV superinfection. Virology 250(1):194–204
Moebes A, Enssle J, Bieniasz PD, Heinkelein M, Lindemann D, Bock M et al (1997) Human foamy virus reverse transcription that occurs late in the viral replication cycle. J Virol 71(10):7305–7311
Yu SF, Sullivan MD, Linial ML (1999) Evidence that the human foamy virus genome is DNA. J Virol 73(2):1565–1572
Erlwein O, McClure MO (2010) Progress and prospects: foamy virus vectors enter a new age. Gene Ther 17(12):1423–1429
Trobridge GD (2009) Foamy virus vectors for gene transfer. Expert Opin Biol Ther 9(11):1427–1436
Schmidt M, Rethwilm A (1995) Replicating foamy virus-based vectors directing high level expression of foreign genes. Virology 210(1):167–178
Russell DW, Miller AD (1996) Foamy virus vectors. J Virol 70(1):217–222
Hirata RK, Miller AD, Andrews RG, Russell DW (1996) Transduction of hematopoietic cells by foamy virus vectors. Blood 88(9):3654–3661
Trobridge GD, Russell DW (1998) Helper-free foamy virus vectors. Hum Gene Ther 9(17):2517–2525
Heinkelein M, Dressler M, Jarmy G, Rammling M, Imrich H, Thurow J et al (2002) Improved primate foamy virus vectors and packaging constructs. J Virol 76(8):3774–3783
Wiktorowicz T, Peters K, Armbruster N, Steinert AF, Rethwilm A (2009) Generation of an improved foamy virus vector by dissection of cis-acting sequences. J Gen Virol 90(Pt 2):481–487
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Gopinath, C., Nathar, T.J., Nelson, E.J.R. (2018). Retroviral Vectors in Gene Therapy. In: Jayandharan, G. (eds) Gene and Cell Therapy: Biology and Applications. Springer, Singapore. https://doi.org/10.1007/978-981-13-0481-1_1
Download citation
DOI: https://doi.org/10.1007/978-981-13-0481-1_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-0480-4
Online ISBN: 978-981-13-0481-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)